A 2-hour experimental biomarker scan in Beijing? Investigational trials that move from idea to patient in 18 months? An American Medical Scientist’s eye-opening trip.
This American medical scientist’s striking experience at a Beijing hospital perfectly complements my earlier post, Why Must Americans Fly to China for Cutting-Edge Cancer Care?
What matters here is not just speed at one hospital. It is the system behind that speed. China’s IIT ecosystem — shaped by reputation effects, physician-led decision-making, and oversight from local ethics and scientific committees — is, in an important sense, more market-oriented than the current American early-stage clinical trial system, because it relies more heavily on real-world judgment by frontline doctors, patients, and institutions, and less on rigid top-down procedures.
My own post approached the issue from the patient side and made a related point: more Western patients are coming to China not simply because China is cheaper, but because China is increasingly able to offer three things that many Western systems are finding harder and harder to provide at the same time: speed, cost predictability, and sufficiently high technical credibility.
For a long time, many people understood “medical tourism” as flying to Southeast Asia for dental work, cosmetic surgery, or routine procedures. But China is entering a much more sophisticated category of decision-making. What is emerging is not a fringe alternative, but a rational cross-border choice built on top-tier hospitals, stronger specialist capacity, fast-moving diagnostic and treatment pathways, and dramatically lower total cost.
That American scientist’s observations — a two-hour experimental biomarker scan, eighteen months from idea to patient, and extremely fast coordination among doctors, hospitals, CDMOs, and research platforms — are not isolated miracles. They are the output of the same institutional logic.
China’s advantage is not simply that it has “more hospitals.” Its strongest capabilities are concentrated inside large tertiary hospitals, where outpatient services, imaging, pathology, inpatient care, and surgery can be tightly integrated within a single organizational structure. On top of that, there is stronger price control, more aggressive procurement discipline, and a physician workforce operating under high-intensity, high-throughput conditions. The result is a system that is structurally better at compressing waiting time, reducing coordination costs, and turning complex medical processes into a more efficient service chain.
So the real question Western systems should be asking is not, “Why was this one scan in China so fast?” The deeper question is: why have so many Western healthcare systems concentrated the worst frictions of medicine precisely where patients are least able to bear them — waiting, referrals, approvals, opaque billing, and fragmented organizational boundaries?
That is why I think this post gets at something important: healthcare is, at its core, also a systems design problem. America’s problem is not an absolute lack of technology, nor a total absence of top hospitals. Its problem is that multi-payer fragmentation, administrative friction, and specialist supply constraints have turned speed itself into a scarce good. In Britain and Canada, the problem looks somewhat different, but the mechanism is similar: budget constraints and queue-based rationing often translate directly into waiting lists.
China is not costless. It has simply chosen a different set of costs. It compresses unit prices, pushes doctors harder, and concentrates top capabilities in exchange for higher throughput and shorter waits. That tradeoff has real downsides. But it also helps explain why, in a growing number of cases, China is starting to look less like a peripheral medical destination and more like a serious alternative for patients who need timely, credible care.
The 60-day default approval at NMPA (deemed approved if no objection raised, post-2018 reform) is the operational expression of what you're describing. FDA's median IND review is 30 days, but the prep work behind that submission averages 12-18 months and seven figures. Speed at the hospital is downstream of speed at the regulator, and increasingly downstream of who is willing to bear the prep cost.
Exactly. This is why formal review timelines can be misleading. A 30-day FDA clock tells you very little if getting to the starting line already takes 12–18 months and seven figures. At that point, the real gatekeeper is not the nominal review period. It is the prep burden.
That is also why China’s speed should be understood as a whole-system phenomenon. Faster hospitals are downstream of faster regulators, and faster regulators are downstream of a system that imposes lower entry friction on early clinical experimentation. The question is no longer just who reviews faster on paper. It is who has built a system in which fewer things have to be painfully assembled before innovation can even touch a patient.
That's a Falun Gong meme. Even the US Department of State concluded that it's bs.
Falun Gong is a business started by a secular scam artist looking to do a pyramid scheme where adherents are forced to continually buy new "holy texts".
The Chinese government crackdown started in 1994 because of the number of people who were going bankrupt from buying all those "holy texts". Then a Falun Gong genius staged an illegal protest in Tiananmen Square and the government decided to just shut the whole cult/scam down. Falun Gong is a business masquerading as a cult (like Scientology) derived from traditional Chinese spiritual and health beliefs (like western yoga) with restrictions on using modern medicine (like Jehovah's Witnesses). It strictly educates and controls what its followers say and do, and is aim directly at taking down the Communist Party of China, so it happily profits from political arbitrage between China and the West.
Falun Gong profits from Western fascination and ignorance of Chinese culture: their Shen Yun is billed as a spectacular Cirque du Soleil-style presentation of Chinese culture that the Communists destroyed. In reality, it’s a Disneyfied caricature of Chinese culture to indoctrinate audiences about Falun Gong. Falun Gong runs a propaganda campaign that’s far more sophisticated than the Communist Party of China. (Maybe they have help from a foreign agency with long experience in that field?)
That is a much more sensitive category, and I would be careful not to confuse speed with legitimacy. In some areas of healthcare, China’s advantage really does come from stronger system coordination, lower friction, and faster execution. But organ transplantation is different. If wait times are unusually short, the question is no longer just institutional efficiency. It is also about donor sourcing, transparency, and whether the process can be independently verified. In that domain, speed by itself is not a clean signal of system strength.
To be fair, China’s officially reported organ donation and transplant volumes have been rising in recent years. In 2024, the official figures reported 6,744 organ donations and 24,684 transplant surgeries. China has also built out a more complete institutional framework over the past decade. Since 2015, voluntary citizen donation has been designated as the only legal source of organs, with the reform presented as being aligned with WHO principles and still undergoing further refinement. That includes new regulations that took effect in 2024, as well as COTRS, the national organ allocation system.
At the level of system design alone, it is entirely plausible that a national allocation platform, a high concentration of major hospitals, a dense cluster of leading transplant centers, and tighter multidisciplinary integration inside large hospitals could shorten the organizational timeline at several points in the process: identifying donors, coordinating across hospitals, retrieving and transporting organs, and moving patients into surgery quickly.
But the American problem is not simply “too few donors.” It is also a system with extremely long waiting lists, complex allocation rules, difficult cross-regional coordination, and much higher compliance and transparency requirements. Both official U.S. data and the GAO have shown that around 2025, the number of people waiting for transplants in the United States was still above 100,000. So long waits in the U.S. do not automatically mean another country is “miraculously efficient.” In many cases, they also reflect the fact that the U.S. is a system with high transparency, dense rules, and heavy oversight — but also very high friction.
This American medical scientist’s striking experience at a Beijing hospital perfectly complements my earlier post, Why Must Americans Fly to China for Cutting-Edge Cancer Care?
https://leonliao.substack.com/p/why-more-western-patients-are-coming
What matters here is not just speed at one hospital. It is the system behind that speed. China’s IIT ecosystem — shaped by reputation effects, physician-led decision-making, and oversight from local ethics and scientific committees — is, in an important sense, more market-oriented than the current American early-stage clinical trial system, because it relies more heavily on real-world judgment by frontline doctors, patients, and institutions, and less on rigid top-down procedures.
My own post approached the issue from the patient side and made a related point: more Western patients are coming to China not simply because China is cheaper, but because China is increasingly able to offer three things that many Western systems are finding harder and harder to provide at the same time: speed, cost predictability, and sufficiently high technical credibility.
For a long time, many people understood “medical tourism” as flying to Southeast Asia for dental work, cosmetic surgery, or routine procedures. But China is entering a much more sophisticated category of decision-making. What is emerging is not a fringe alternative, but a rational cross-border choice built on top-tier hospitals, stronger specialist capacity, fast-moving diagnostic and treatment pathways, and dramatically lower total cost.
That American scientist’s observations — a two-hour experimental biomarker scan, eighteen months from idea to patient, and extremely fast coordination among doctors, hospitals, CDMOs, and research platforms — are not isolated miracles. They are the output of the same institutional logic.
China’s advantage is not simply that it has “more hospitals.” Its strongest capabilities are concentrated inside large tertiary hospitals, where outpatient services, imaging, pathology, inpatient care, and surgery can be tightly integrated within a single organizational structure. On top of that, there is stronger price control, more aggressive procurement discipline, and a physician workforce operating under high-intensity, high-throughput conditions. The result is a system that is structurally better at compressing waiting time, reducing coordination costs, and turning complex medical processes into a more efficient service chain.
So the real question Western systems should be asking is not, “Why was this one scan in China so fast?” The deeper question is: why have so many Western healthcare systems concentrated the worst frictions of medicine precisely where patients are least able to bear them — waiting, referrals, approvals, opaque billing, and fragmented organizational boundaries?
That is why I think this post gets at something important: healthcare is, at its core, also a systems design problem. America’s problem is not an absolute lack of technology, nor a total absence of top hospitals. Its problem is that multi-payer fragmentation, administrative friction, and specialist supply constraints have turned speed itself into a scarce good. In Britain and Canada, the problem looks somewhat different, but the mechanism is similar: budget constraints and queue-based rationing often translate directly into waiting lists.
China is not costless. It has simply chosen a different set of costs. It compresses unit prices, pushes doctors harder, and concentrates top capabilities in exchange for higher throughput and shorter waits. That tradeoff has real downsides. But it also helps explain why, in a growing number of cases, China is starting to look less like a peripheral medical destination and more like a serious alternative for patients who need timely, credible care.
The 60-day default approval at NMPA (deemed approved if no objection raised, post-2018 reform) is the operational expression of what you're describing. FDA's median IND review is 30 days, but the prep work behind that submission averages 12-18 months and seven figures. Speed at the hospital is downstream of speed at the regulator, and increasingly downstream of who is willing to bear the prep cost.
Exactly. This is why formal review timelines can be misleading. A 30-day FDA clock tells you very little if getting to the starting line already takes 12–18 months and seven figures. At that point, the real gatekeeper is not the nominal review period. It is the prep burden.
That is also why China’s speed should be understood as a whole-system phenomenon. Faster hospitals are downstream of faster regulators, and faster regulators are downstream of a system that imposes lower entry friction on early clinical experimentation. The question is no longer just who reviews faster on paper. It is who has built a system in which fewer things have to be painfully assembled before innovation can even touch a patient.
They are also real good at finding organ donors. I think the wait time is two weeks.
That's a Falun Gong meme. Even the US Department of State concluded that it's bs.
Falun Gong is a business started by a secular scam artist looking to do a pyramid scheme where adherents are forced to continually buy new "holy texts".
The Chinese government crackdown started in 1994 because of the number of people who were going bankrupt from buying all those "holy texts". Then a Falun Gong genius staged an illegal protest in Tiananmen Square and the government decided to just shut the whole cult/scam down. Falun Gong is a business masquerading as a cult (like Scientology) derived from traditional Chinese spiritual and health beliefs (like western yoga) with restrictions on using modern medicine (like Jehovah's Witnesses). It strictly educates and controls what its followers say and do, and is aim directly at taking down the Communist Party of China, so it happily profits from political arbitrage between China and the West.
Falun Gong profits from Western fascination and ignorance of Chinese culture: their Shen Yun is billed as a spectacular Cirque du Soleil-style presentation of Chinese culture that the Communists destroyed. In reality, it’s a Disneyfied caricature of Chinese culture to indoctrinate audiences about Falun Gong. Falun Gong runs a propaganda campaign that’s far more sophisticated than the Communist Party of China. (Maybe they have help from a foreign agency with long experience in that field?)
That is a much more sensitive category, and I would be careful not to confuse speed with legitimacy. In some areas of healthcare, China’s advantage really does come from stronger system coordination, lower friction, and faster execution. But organ transplantation is different. If wait times are unusually short, the question is no longer just institutional efficiency. It is also about donor sourcing, transparency, and whether the process can be independently verified. In that domain, speed by itself is not a clean signal of system strength.
To be fair, China’s officially reported organ donation and transplant volumes have been rising in recent years. In 2024, the official figures reported 6,744 organ donations and 24,684 transplant surgeries. China has also built out a more complete institutional framework over the past decade. Since 2015, voluntary citizen donation has been designated as the only legal source of organs, with the reform presented as being aligned with WHO principles and still undergoing further refinement. That includes new regulations that took effect in 2024, as well as COTRS, the national organ allocation system.
At the level of system design alone, it is entirely plausible that a national allocation platform, a high concentration of major hospitals, a dense cluster of leading transplant centers, and tighter multidisciplinary integration inside large hospitals could shorten the organizational timeline at several points in the process: identifying donors, coordinating across hospitals, retrieving and transporting organs, and moving patients into surgery quickly.
But the American problem is not simply “too few donors.” It is also a system with extremely long waiting lists, complex allocation rules, difficult cross-regional coordination, and much higher compliance and transparency requirements. Both official U.S. data and the GAO have shown that around 2025, the number of people waiting for transplants in the United States was still above 100,000. So long waits in the U.S. do not automatically mean another country is “miraculously efficient.” In many cases, they also reflect the fact that the U.S. is a system with high transparency, dense rules, and heavy oversight — but also very high friction.
China is the new shiny city on the hill. Don’t cha know? Follow the damn money.
If you want to know what the future looks like… follow the money.